| 000 | 01716 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250517025501.0 | ||
| 264 | 0 | _c20160218 | |
| 008 | 201602s 0 0 eng d | ||
| 022 | _a2212-3970 | ||
| 024 | 7 |
_a10.2174/1574892810666150416111831 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPornour, Majid | |
| 245 | 0 | 0 |
_aNew perspective therapy of breast cancer based on selective dopamine receptor D2 agonist and antagonist effects on MCF-7 cell line. _h[electronic resource] |
| 260 |
_bRecent patents on anti-cancer drug discovery _c2015 |
||
| 300 |
_a214-23 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aBromocriptine _xadministration & dosage |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 |
_aDopamine Agonists _xadministration & dosage |
| 650 | 0 | 4 |
_aDopamine D2 Receptor Antagonists _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMCF-7 Cells |
| 650 | 0 | 4 | _aPatents as Topic |
| 650 | 0 | 4 |
_aProliferating Cell Nuclear Antigen _xgenetics |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xagonists |
| 650 | 0 | 4 |
_aRemoxipride _xadministration & dosage |
| 700 | 1 | _aAhangari, Ghasem | |
| 700 | 1 | _aHejazi, Seyed H | |
| 700 | 1 | _aDeezagi, Abdolkhalegh | |
| 773 | 0 |
_tRecent patents on anti-cancer drug discovery _gvol. 10 _gno. 2 _gp. 214-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/1574892810666150416111831 _zAvailable from publisher's website |
| 999 |
_c24807303 _d24807303 |
||